You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel sensor for the real-time measurement of mitral coaptation force
SBC: MitralPint Inc. Topic: NHLBIProject Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text
SBC: GRAYRAIN, LLC Topic: NCATSPROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Structure-based computational engineering of saCas9 PAM requirement
SBC: ATGC Inc. Topic: 400ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis
SBC: TARN BIOSCIENCES, INC. Topic: NIAIDTarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States
SBC: NEW MEXICO START-UP FACTORY II LLC Topic: NIGMSProject Summary As a participant in the new IDeA Regional Entrepreneurship Development (I-RED) program, the goal of this proposal is to create an educational product to promote entrepreneurism and commercialization in the Mountain West region of IDeA states. The educational product and overall program are intended to address the needs of IDeA state academic institutions in developing and strengthe ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Genome Editing Therapy for Usher Syndrome Type 3
SBC: GENETOBE INC Topic: NEIPROJECT SUMMARY/ABSTRACTUsher syndrome type 3A (USH3A), an autosomal recessive disorder, is characterized by progressive loss of hearing and vision due to a clarin-1 (CLRN1) gene mutation. A person with type 3 Usher syndrome will usually require cochlea implants by mid- to late adulthood and classified as being legally blind. The management of the chronic, progressive, severe vision loss (retiniti ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Towards intra-operative guidance in brain tumor surgery using real-time resting-state functional MRI
SBC: NeurInsight, LLC Topic: NINDSSummaryResting-state functional MRI (rsfMRI) is a rapidly developing task-free approach for presurgical mapping. It can complement task-based functional MRI (tfMRI) in patients who have difficulties performing tasks and efficiently map resting state networks (RSNs) in regions that are not typically mapped with tfMRI due to time constraints, such as frontal cortex. It has the potential to provide i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Precision Medicine for Alcohol-Associated Liver Disease
SBC: GENETOBE INC Topic: 150ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health